Inflammatory Ocular Disease Treatment 'RCI001' Demonstrates Effectiveness in Treatment of Sjogren Syndrome
Oct 22, 2024
Professor Kim Dong-hyun of ophthalmology at Korea University Anam Hospital demonstrated the effectiveness of the new inflammatory eye disease treatment 'RCI001' to treat Sjogren syndrome. Sjogren syndrome is an autoimmune disease in which the salivary glands and tear glands are chronically inflamed, characterized by dry mouth and dry eyes. It occurs mainly in the elderly, and symptomatic relief has been used because there is no fundamental treatment so far.
Anti-inflammatory drugs such as artificial tears, topical corticosteroids, cyclosporin A, and Lifitegrast are being used to treat dry eyes caused by Sjogren syndrome, but there were problems with limited effects or poor eye lining. In particular, steroids can cause glaucoma when used for a long time, so the need for new treatments has been raised.
The research team administered RCI001 and PBS (phosphoric acid-buffered saline) twice a day for a week through environmental dry eye animal experiments, and confirmed the amount of tear secretion on the eyeball surface, the inflammation of the tear glands in the conjunctiva and cornea, and the immune response.
As a result of the study, it was found that the group receiving RCI001 after 1 week of treatment had more ocular surface tear secretion than the PBS group (p-value < 0.05). Proteins that cause inflammation in the conjunctiva and tear glands (inflammatory cytokines IL-1β, IL-17) were also significantly reduced in the RCI001 group (p-value <0.05), and the degree of cell damage (oxidative stress marker 4-hydroxy-2-nonenal, hexanoyl-lysine, NOX4) that could cause a negative response to the immune system was also found to be less.
Professor Kim Dong-hyun "This study confirmed that RCI001 has a low risk of inflammation and cell damage."It is expected to present safer and more effective treatments for patients with Sjogren syndrome who need to administer eye treatments for life."
Meanwhile, this study 'Efficacy of RCI001 as a Therapeutics Candidate in a Primary Sjoren Syndrome House Model' was published in the September issue of the International Journal (CORNEA) specializing in ophthalmic and corneal research.
Anti-inflammatory drugs such as artificial tears, topical corticosteroids, cyclosporin A, and Lifitegrast are being used to treat dry eyes caused by Sjogren syndrome, but there were problems with limited effects or poor eye lining. In particular, steroids can cause glaucoma when used for a long time, so the need for new treatments has been raised.
The research team administered RCI001 and PBS (phosphoric acid-buffered saline) twice a day for a week through environmental dry eye animal experiments, and confirmed the amount of tear secretion on the eyeball surface, the inflammation of the tear glands in the conjunctiva and cornea, and the immune response.
As a result of the study, it was found that the group receiving RCI001 after 1 week of treatment had more ocular surface tear secretion than the PBS group (p-value < 0.05). Proteins that cause inflammation in the conjunctiva and tear glands (inflammatory cytokines IL-1β, IL-17) were also significantly reduced in the RCI001 group (p-value <0.05), and the degree of cell damage (oxidative stress marker 4-hydroxy-2-nonenal, hexanoyl-lysine, NOX4) that could cause a negative response to the immune system was also found to be less.
Professor Kim Dong-hyun "This study confirmed that RCI001 has a low risk of inflammation and cell damage."It is expected to present safer and more effective treatments for patients with Sjogren syndrome who need to administer eye treatments for life."
Meanwhile, this study 'Efficacy of RCI001 as a Therapeutics Candidate in a Primary Sjoren Syndrome House Model' was published in the September issue of the International Journal (CORNEA) specializing in ophthalmic and corneal research.
|
bellho@sportschosun.com
